William Blair Lifts Target on Idenix (IDIX) to $14 Following Removal of Clinical Hold

William Blair's Katherine Xu boosted her price target on shares of Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) by 40 percent from $10 to $14 in an earlier research note Friday. Xu maintains an Outperform rating on Idenix Pharma.

Although Idenix shares are down more than 12 percent this afternoon amid an update from Gilead (Nasdaq: GILD) on its '7977, Idenix announced this morning the removal of a clinical hold on its IDX184. In an earlier note from Xu, the analyst said a buyout of Idenix would not happen until after the hold was removed.

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Downgrades Shanghai Chicmax Cosmetic (2145:HK) to Neutral
• Palo Alto Networks (PANW) PT Raised to $430 at Scotiabank
• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'